A clinical pharmacology study led by Otani, Payne and Loftus showed a single 2‑ml subcutaneous injection of mirikizumab is bioequivalent to two separate 1‑ml injections in healthy volunteers. The finding supports a simplified dosing regimen for future clinical practice and supply-chain efficiency. The trial measured pharmacokinetics and safety endpoints and concluded comparable exposure and tolerability between the two dosing formats. Authors note operational advantages—fewer injections per visit and potential device consolidation—that could improve patient adherence in chronic indications. Clarification: Mirikizumab is a monoclonal antibody in development for inflammatory diseases; bioequivalence of different administration volumes can streamline dosing and improve patient experience.